Literature DB >> 8362831

Gastric mucosal hydrophobicity and Helicobacter pylori: response to antimicrobial therapy.

M F Go1, G M Lew, L M Lichtenberger, R M Genta, D Y Graham.   

Abstract

The hydrophobic properties of the gastric mucosa are reduced by NSAIDs and by Helicobacter pylori infection. Our investigation was to determine whether this abnormality was due to the bacteria or to the inflammatory response. Contact angle measurements were made on gastric antral and corpus biopsies taken from 10 H. pylori-infected volunteers before eradication therapy, after 2 and 14 days of therapy, and 4 weeks after therapy. The contact angle improved steadily and statistically throughout the 2 weeks of therapy (for day 0, 3, 14, respectively) antral mucosa 54.2 +/- 2, 59.3 +/- 2, and 63.2 +/- 2; corpus mucosa 55 +/- 1, 57.8 +/- 3, and 66.6 +/- 1. After 2 days of therapy, H. pylori bacteria were no longer evident, and yet the contact angle continued to improve, suggesting that bacteria and bacterial products (e.g., lipases) may not be critical factors. H. pylori was eradicated in five and failed in five. One month after ending therapy, the contact angles of those with recrudescence of infection and those with eradication were similar and higher (p < 0.05) than before therapy (antrum: 69.8 +/- 1 vs. 71.1 +/- 2, corpus: 66.4 +/- 4 vs. 70.8 +/- 2) (p > 0.25 for both). We conclude that gastric surface hydrophobicity abnormalities do not appear to be directly related to the presence of H. pylori organisms or the histologic features of acute inflammation, but are responsive to antimicrobial therapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8362831

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  6 in total

1.  Characterization of virulence factors of mouse-adapted Helicobacter pylori strain SS1 and effects on gastric hydrophobicity.

Authors:  A S Day; N L Jones; Z Policova; H A Jennings; E K Yau; P Shannon; A W Neumann; P M Sherman
Journal:  Dig Dis Sci       Date:  2001-09       Impact factor: 3.199

2.  Restorative impact of rabeprazole on gastric mucus and mucin production impairment during naproxen administration: its potential clinical significance.

Authors:  T Jaworski; I Sarosiek; S Sostarich; K Roeser; M Connor; S Brotze; G Wallner; J Sarosiek
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

3.  Significant enhancement of gastric mucin content after rabeprazole administration: its potential clinical significance in acid-related disorders.

Authors:  T Skoczylas; I Sarosiek; S Sostarich; C McElhinney; S Durham; J Sarosiek
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

Review 4.  Helicobacter pylori: the new bug on the (paraffin) block.

Authors:  R M Genta; D Y Graham
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

5.  Gastrointestinal safety and therapeutic efficacy of parenterally administered phosphatidylcholine-associated indomethacin in rodent model systems.

Authors:  L M Lichtenberger; J J Romero; E J Dial
Journal:  Br J Pharmacol       Date:  2009-04-20       Impact factor: 8.739

6.  Advent of novel phosphatidylcholine-associated nonsteroidal anti-inflammatory drugs with improved gastrointestinal safety.

Authors:  Yun Jeong Lim; Elizabeth J Dial; Lenard M Lichtenberger
Journal:  Gut Liver       Date:  2012-11-13       Impact factor: 4.519

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.